Agios Pharmaceuticals AGIO Stock
Agios Pharmaceuticals Price Chart
Agios Pharmaceuticals AGIO Financial and Trading Overview
| Agios Pharmaceuticals stock price | 32.81 USD |
| Previous Close | 33.6 USD |
| Open | 33.83 USD |
| Bid | 24.39 USD x 200 |
| Ask | 42.86 USD x 200 |
| Day's Range | 33.16 - 34.36 USD |
| 52 Week Range | 22.24 - 46 USD |
| Volume | 33.28K USD |
| Avg. Volume | 1.11M USD |
| Market Cap | 1.99B USD |
| Beta (5Y Monthly) | 0.6 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.92 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.75 USD |
AGIO Valuation Measures
| Enterprise Value | 1.42B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.458022 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.268332 |
| Price/Book (mrq) | 1.9394096 |
| Enterprise Value/Revenue | 14.436 |
| Enterprise Value/EBITDA | -3.129 |
Trading Information
Agios Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.6 |
| 52-Week Change | -7.43% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 46 USD |
| 52 Week Low | 22.24 USD |
| 50-Day Moving Average | 35.35 USD |
| 200-Day Moving Average | 30.59 USD |
AGIO Share Statistics
| Avg. Volume (3 month) | 1.11M USD |
| Avg. Daily Volume (10-Days) | 763.54K USD |
| Shares Outstanding | 59.7M |
| Float | 50.02M |
| Short Ratio | 7.17 |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 112.28% |
| Shares Short | 7.54M |
| Short % of Float | 12.75% |
| Short % of Shares Outstanding | 12.62% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -247.070% |
| Gross Margin | -270.79% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.24% |
| Return on Equity (ttm) | -34.33% |
Income Statement
| Revenue (ttm) | 98.34M USD |
| Revenue Per Share (ttm) | 1.68 USD |
| Quarterly Revenue Growth (yoy) | 259.30% |
| Gross Profit (ttm) | -266288992 USD |
| EBITDA | -453671008 USD |
| Net Income Avi to Common (ttm) | -411286016 USD |
| Diluted EPS (ttm) | -7.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 617.58M USD |
| Total Cash Per Share (mrq) | 10.34 USD |
| Total Debt (mrq) | 31.17M USD |
| Total Debt/Equity (mrq) | 3.04 USD |
| Current Ratio (mrq) | 10.221 |
| Book Value Per Share (mrq) | 17.214 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -360596000 USD |
| Levered Free Cash Flow (ttm) | -274604000 USD |
Profile of Agios Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 88 Sidney Street |
| ZIP | 02139 |
| Phone | 617 649 8600 |
| Website | https://www.agios.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 539 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Q&A For Agios Pharmaceuticals Stock
What is a current AGIO stock price?
Agios Pharmaceuticals AGIO stock price today per share is 32.81 USD.
How to purchase Agios Pharmaceuticals stock?
You can buy AGIO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Agios Pharmaceuticals?
The stock symbol or ticker of Agios Pharmaceuticals is AGIO.
Which industry does the Agios Pharmaceuticals company belong to?
The Agios Pharmaceuticals industry is Biotechnology.
How many shares does Agios Pharmaceuticals have in circulation?
The max supply of Agios Pharmaceuticals shares is 59.7M.
What is Agios Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Agios Pharmaceuticals PE Ratio is now.
What was Agios Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Agios Pharmaceuticals EPS is -6.92 USD over the trailing 12 months.
Which sector does the Agios Pharmaceuticals company belong to?
The Agios Pharmaceuticals sector is Healthcare.
Agios Pharmaceuticals AGIO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25981.57 USD — |
-0.78
|
7.07B USD — | 25943.31 USD — | 26172.12 USD — | — - | 7.07B USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3591.58 USD — |
+0.65
|
99.81M USD — | 3541.87 USD — | 3599.27 USD — | — - | 99.81M USD — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7526.03 USD — |
-1.41
|
— — | 7475.1 USD — | 7620.74 USD — | — - | — — |
|
US Tech US 700 Small Cap Value N
NQUS700SCVN
US
|
3060.88 USD — |
-0.1
|
— — | 3054.84 USD — | 3068.7 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3054.14 USD — |
-0.57
|
— — | 3045.52 USD — | 3067.04 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech US BuyBack Achievers Sel
DRBS
US
|
2340.09 USD — |
+0.42
|
— — | 2336.31 USD — | 2349.71 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32087.45 USD — |
-0.78
|
— — | 32040.2 USD — | 32322.77 USD — | — - | — — |
|
US Tech US 700 Small Cap Value I
NQUS700SCV
US
|
2664.73 USD — |
-0.12
|
— — | 2659.47 USD — | 2671.53 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12769.21 USD — |
-0.76
|
— — | 12750.37 USD — | 12862.09 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6887.9 USD — |
-1.46
|
— — | 6841.27 USD — | 6974.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1294.5 USD — |
-1.07
|
— — | 1285.37 USD — | 1305.11 USD — | — - | — — |
|
US Tech Global BuyBack Achievers
DRBG
US
|
3170.93 USD — |
+0.1
|
— — | 3164.46 USD — | 3171.48 USD — | — - | — — |
- {{ link.label }} {{link}}
